BOSTON, Aug. 21 /PRNewswire/ -- Surface Logix is pleased to announce the appointment of Leland Webster, Ph.D., M.B.A., as Vice President, Corporate Development. As a member of the management team, Dr. Webster will primarily be responsible for leading the development and execution of Surface Logix’s business strategy and corporate partnering activities. Dr. Webster will also have responsibility for corporate communications.
“I am extremely pleased to welcome Leland to the Surface Logix management team. I look forward to working with him as we near Phase IIa proof of concept for our two lead compounds, SLx-2101 and SLx-4090, the achievement of which will result in significant value creation in the context of partnering and funding discussions,” said Jim Mahoney, CEO of Surface Logix. “Leland’s scientific background combined with his business training and 11 years of biotechnology industry experience in business development brings a valuable mix of skills and experience to our company as we continue to both advance our clinical programs and exploit our core Pharmacomer(TM) Technology.”
Prior to joining Surface Logix, Dr. Webster led business development at ImmunoGen, Inc., most recently as an Executive Director. Previously, he held positions of increasing responsibility in business development at Vertex Pharmaceuticals. Before that, Dr. Webster was a Senior Analyst at MPM Capital L.P.
Dr. Webster holds a B.A. in Biological Sciences from Northwestern University and a Ph.D. in Biochemistry from the University of Pennsylvania, and served as a Damon Runyon-Walter Winchell postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at the Harvard Medical School. Dr. Webster also earned an M.B.A. from the MIT Sloan School of Management.
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create and develop novel small molecule drugs (NCEs) with superior intrinsic drug- like properties that are clearly differentiated from competitive products. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com .
Contact: Leland Webster, Ph.D., M.B.A. Surface Logix Inc. Vice President, Corporate Development 617.746.8520 Media: Kari Watson MacDougall Biomedical Communications Inc. kwatson@macbiocom.com 508.647.0209
Surface Logix Inc.
CONTACT: Leland Webster, Ph.D., M.B.A, Vice President, CorporateDevelopment of Surface Logix Inc., +1-617-746-8520, or Kari Watson ofMacDougall Biomedical Communications Inc., +1-508-647-0209,kwatson@macbiocom.com, for Surface Logix Inc.
Web site: http://www.surfacelogix.com/
